Updates on the Perioperative Management of Resectable Non-Small Cell Lung Cancer.
Stacey M Frumm, Narjust Florez, Jay M Lee...
https://pubmed.ncbi.nlm.nih.gov/41911908/Actively Recruiting
Led by National Cancer Institute (NCI) · Updated on 2026-11-04
1210
Participants Needed
1151
Research Sites
N/A
Total Duration
Researchers are evaluating the addition of pembrolizumab, a type of immunotherapy, to standard chemotherapy for patients with stage IIA, IIB, IIIA, or IIIB non-small cell lung cancer NSCLC that has been completely removed by surgery. This phase III trial aims to compare disease-free survival and overall survival between different treatment approaches, including chemotherapy alone and chemotherapy combined with pembrolizumab. The study also investigates side effects, drug discontinuation rates, quality of life, and specific biomarkers such as PD-L1 expression and tumor mutational burden. Participants are randomly assigned to one of two treatment groups. Both groups initially receive one of four chemotherapy regimens every 21 days for four cycles, chosen by their doctor. In one group, pembrolizumab is given after chemotherapy as an intravenous infusion every 21 days for up to 17 cycles or every 6 weeks for up to 16 cycles. In the other group, pembrolizumab is given together with chemotherapy during the initial cycles and then continued as monotherapy. Patients undergo various scans and blood tests throughout the study, including echocardiograms, MRIs, CT scans, and blood sample collections. During the trial, participants are closely monitored for disease status and side effects. Follow-up visits occur six weeks after treatment, then every three months for two years, every six months for years two to four, and annually for up to ten years after randomization. Quality of life questionnaires and symptom assessments are also completed. The main measure of success is disease-free survival, tracked for up to five years after enrollment. Safety and overall survival are reviewed for up to ten years to ensure long-term monitoring.
CONDITIONS
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Cancer Institute (NCI)
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Chemotherapy, then sequential pembrolizumab | Standard chemotherapy, then observation | Chemotherapy plus pembrolizumab given together |
|---|---|---|---|
| What it is | Participants first receive standard platinum-doublet chemotherapy, then immunotherapy with pembrolizumab is given sequentially as adjuvant treatment. | Participants receive a standard platinum-based doublet chemotherapy regimen after complete surgical resection, followed by an observation period with no additional systemic therapy. | Participants receive platinum-based chemotherapy and pembrolizumab together concurrently. |
| Primary use in this trial | Adjuvant chemotherapy followed by pembrolizumab to determine if sequential immunotherapy can further reduce recurrence or improve survival. | Adjuvant therapy after lung cancer surgery, aiming to reduce disease recurrence risk. | Concurrent chemotherapy and pembrolizumab as adjuvant treatment to evaluate if simultaneous combination improves outcomes compared to chemo alone. |
| How it is given or performed | Participants complete intravenous chemotherapy first. Pembrolizumab immunotherapy is then infused IV on a scheduled basis after chemo is finished. | Adjuvant chemotherapy is administered intravenously as a platinum-based doublet (cisplatin or carboplatin plus a second agent) for several cycles after surgery. No additional systemic therapy is given during observation. | Both platinum-based chemotherapy and pembrolizumab are administered intravenously at the same time (concurrently) during the adjuvant treatment period. |
| Evidence status / maturity | The benefit of adding pembrolizumab sequentially to chemotherapy is still being studied; mature randomized data are not yet available. | Platinum-doublet adjuvant chemotherapy after surgery is supported by multiple randomized studies showing improved survival in stage II-III NSCLC. | It is not yet known if combining pembrolizumab with chemotherapy in the adjuvant setting further improves survival; this is under investigation. |
| Important limitations (design, maturity, or current evidence) | Sequential use of pembrolizumab after chemotherapy is investigational and not yet supported by large mature outcome data, so its potential added benefit or harms are uncertain at present. | Adjuvant chemotherapy, while established, is associated with significant short-term side effects, and not all eligible patients are able to tolerate the regimen. | Combining immunotherapy with chemotherapy is being studied for both potential benefit and potential increased toxicity; long-term results for the adjuvant setting are unavailable. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 12 weeks
Participants receive one of four chemotherapy regimens every 21 days for 4 cycles based on the doctor's choice, provided there is no disease progression or unacceptable side effects.
4 visits (every 3 weeks)
Duration - Up to 54 weeks
Participants receive pembrolizumab intravenously either sequentially after chemotherapy or concurrently with chemotherapy followed by pembrolizumab alone. This treatment repeats every 21 days or every 6 weeks for up to 16-17 cycles depending on enrollment date and treatment arm.
Regular visits every 3 or 6 weeks depending on schedule
Duration - Up to 10 years
Participants are monitored after treatment completion with visits at 6 weeks, then every 3 months for 2 years, every 6 months for years 2 to 4, and annually up to 10 years to check for disease status and side effects.
Multiple follow-up visits as scheduled
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Stacey M Frumm, Narjust Florez, Jay M Lee...
https://pubmed.ncbi.nlm.nih.gov/41911908/Jacob M Sands, Sumithra J Mandrekar, David Kozono...
https://pubmed.ncbi.nlm.nih.gov/33878954/Raymond U Osarogiagbon, Jeremy P Cetnar, Raid Aljumaily
https://pubmed.ncbi.nlm.nih.gov/42335416/Allison Booth, Shauna Hillman, Kristina Laumann...
https://pubmed.ncbi.nlm.nih.gov/41747891/National Cancer Institute (NCI)
Lead Sponsor